Last reviewed · How we verify
NCT06836700: Trifecta
Comparison of Trifecta Analysis of Standard Versus Mini Percutaneous Nephrolithotomy in the Management of Urolithiasis
NA trial testing Mini PCNL in Renal Stones in 180 participants. Completed in 15 March 2024.
10 March 2024
Quick facts
| Lead sponsor | Hayat Abad Medical Complex, Peshawar |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 180 |
| Start date | 10 January 2022 |
| Primary completion | 10 March 2024 |
| Estimated completion | 15 March 2024 |
| Sites | 1 location across Pakistan |
Drugs / interventions tested
- Mini PCNL
Conditions studied
- Renal Stones — all drugs for Renal Stones →
- Urolithiasis, Calcium Oxalate — all drugs for Urolithiasis, Calcium Oxalate →
Sponsor
Hayat Abad Medical Complex, Peshawar — full company profile →
Who can join
Adults 16 to 65, any sex, with Renal Stones or Urolithiasis, Calcium Oxalate. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Introduction: Urolithiasis is a common urological condition, and percutaneous nephrolithotomy (PCNL) is a widely used treatment option. Trifecta analysis, which includes stone-free rate, reduced complications (Clavien- Dindo classification), and minimal need for auxiliary procedures, provides a standardized way to compare outcomes. This study evaluates the trifecta outcomes of standard PCNL and mini PCNL.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06836700
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Hayat Abad Medical Complex, Peshawar trials
Trials by the same sponsor.
- NCT07055529 — Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of General · EARLY_PHASE1 · not yet recruiting
- NCT07453238 — Comparison of Topical Calcipotriol and Intralesional Steroids in Alopecia Areata · Phase 4 · not yet recruiting
- NCT07437534 — Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) fo · Phase 4 · not yet recruiting
- NCT07406204 — Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA) · Phase 4 · not yet recruiting
- NCT07441005 — Comparative Efficacy of Topical Oxiconazole Cream (1%) Versus Topical Clotrimazole Cream (1%) in the Treatment of Tinea · EARLY_PHASE1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06836700 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hayat Abad Medical Complex, Peshawar
- Last refreshed: 20 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06836700.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing